AstraZeneca at a Glance

We are a global, science-led, patient-focused pharmaceutical business. We are dedicated to transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet.

Our strategic priorities

Our priorities reflect how we are working to deliver our Growth Through Innovation strategy and achieve our Purpose of pushing the boundaries of science to deliver life-changing medicines.

1. Science and Innovation
2. Growth and Therapy Area Leadership
3. People and Sustainability

Science and innovation-led

We use our distinctive scientific capabilities to deliver a pipeline of life-changing medicines.

178
projects in our development pipeline[1]

17
new molecular entities (NMEs) in our late-stage pipeline

123
NME or major life-cycle management (LCM) projects in Phase II and Phase III

[1] Includes NME and major LCM projects up to launch in all applicable major markets.

Leading in our Therapy Areas

We are focused on areas where we can make the most meaningful difference to patients.

Therapy Areas

Oncology
BioPharmaceuticals
Rare Disease

Total Revenue[2]

$45.8bn

[2] Total Revenue includes revenues from Other Medicines.

Diversified portfolio and global reach

With a focus on patients, we have a global reach and a diversified portfolio of medicines across primary care, specialty care and rare diseases.

Total Revenue by Therapy Area



- Oncology 40%
- BioPharmaceuticals 40%
- Rare Disease 17%
- Other Medicines 3%

Total Revenue by reporting region



- US 42%
- Emerging Markets 26%
- Europe 21%
- Established Rest of World 11%

Positively impacting people, society and the planet BV

We are committed to operating in a way that recognises the interconnection between business growth, the needs of society and the limitations of our planet.

66.4m
people reached by our access to healthcare programmes

67.6%
reduction in Scope 1 and 2 GHG emissions since 2015

MSCI ESG RATINGS AA

Rating of AA in the MSCI ESG Ratings assessment

MEMBER OF Dow Jones Sustainability Indices In Collaboration with RobecoSAM

Top 20% of 2,500 of the world's largest companies and Europe Index constituent